To learn the toxicity of xenogeneic tumor-specific immune ribonucleic acid (I-RNA), experimental and clinical studies were carried out. Experimentally, doses of 30 mg/kg , 15 mg/kg, 7.5 mg/kg or 3.75 mg/kg of xenogeneic I-RNA extracted from lymphoid tissues of rabbits sensitized with 105,000 x g sediments of human gastric carcinoma tissue were injected intraperitoneally into Wistar rats once a day for 30 days.
During the period of the study, changes of physiological and biochemical values were examined.
In addition, pathological study was made for each organ after the I-RNA administration.
There was no death during the study.
In the groups of high dose administration, there were poor increase in body weight, elevation of GOT, GPT and LDH, findings of vacuolar degenera tion of hepatic cells, and increase of mesangial matrix and polynuclear glomerulus. Throughout the experiment, the groups given 7.5 mg/kg and 3.75 mg/kg of I-RNA showed no significant difference from control groups. Clinically, 31 cases treated with passive immunotherapy with allogeneic lymphocytes, preincubated with xenogeneic I-RNA, were examined retrospectively for the difference in hematological and biochemical data before and after the therapy. One case showed a transient mild febrile reaction after the therapy.
There was no significant difference in hematological and biochemical data. Pathological findings in 3 autopsies after the treatment were reported. xenogeneic immune-RNA; toxicity Alexander et al. (1967) reported the successful mediation of antitumor immunity by RNA extracted from lymphoid tissue of animals immunized with the tumor. Subsequently, Pilch et al. (1974) demonstrated the ability of xenogeneic I-RNA to mediate tumor specific responses in animal as well as human tumors.
They also showed that non-immune human lymphocytes preincubated with xenogeneic I-RNA could be converted to effector cells, which were specifically cytotoxic to human tumor cells (melanoma, gastric cancer and breast cancer).
In recent years, the authors (Fukushima et al. 1974; Ishikawa et al. 1978) performed experimental and clinical studies on the antitumor effect of I-RNA, and Immunization and extraction of RNA. The methods of immunization and extraction of RNA were previously described in detail (Fukushima et al. 1974 ). Briefly, the antigen (105,000 x g sediment) corresponding to about 0.3 g of tumor was dissolved in 2 ml of normal saline solution and injected into several rabbits intramuscularly at weekly intervals for 3 consecutive weeks. RNA was extracted from their spleens, lymph nodes and WBC by the method of Ralph and Bellamy (Ralph and Bellamy 1964) seven days after the last injection of tumor antigen.
The properties of the extracted RNA were routinely examined both with ultraviolet absorption spectroscopy and Schlieren optics by analytical centrifuge.
The results of pyrogen test and Biuret reaction were negative. An acute toxicity test was carried out by injection of 900 mg/kg of extracted RNA intraperitoneally into 12 rats, and all of them survived without any complications. Experimental groups and observation of the toxicity. Six groups each consisting of six Wistar rats were used for the experiment.
The doses of 30mg/kg (50 times the regular dose of 0.6 mg/kg), 15 mg/kg (25-fold), 7.5 mg/kg (12.5-fold), and 3.75 mg/kg (6.25-fold) of previously extracted xenogeneic I-RNA were injected into experimental groups A, B, C and D, respectively, intraperitoneally in 1.0 ml of normal saline solution every day for 30 days. One ml of normal saline solution was injected into the control group E intraperitoneally every day for 30 days, and no treatment was done for the control group F.
In order to observe the toxicity of I-RNA, the amount of oral intake and change of body weight of each rat were examined at weekly intervals.
On the day following the termination of I-RNA injection, blood was drawn from the heart of each rat under ether anesthesia for the determination of hematological and biochemical data, and each organ was sent for pathological examination. Preparation of xenogeneic tumor-specific I-RNA . As described in detail previously (Fukushima et al. 1974 ), several rabbits were injected intramuscularly with each patient's antigen corresponding to about 0.3 g of tumor tissue at weekly intervals for 3 con secutive weeks. RNA was extracted from their spleens, lymph nodes and WBC by the Ralph and Bellamy method 7 days after the last injection. Method of study on the toxicity. The patient's clinical status was fully evaluated including physical, hematological and biochemical examinations before and after the immunotherapy to determine any evidence of side effects. Three patients who died of gastric cancer after the immunotherapy were autopsied and pathological findings were evaluated for each organ. Five cases of gastric cancer without any immunotherapy were studied by autopsy as a control group.
RESULTS

Experimental study
Oral intake and body weight. In group A with 30 mg/kg I-RNA administra tion, there was a significant decrease in oral intake after the second week . On ;he other hand, there was no decrease in other groups .
In groups A and B, the increasing ratios of body weight were 1.83 and 1.84, respectively, which were less than those for the control groups E and F (Fig. 1,  Table 2 ). Fig. 1 . The change of average body weight in each experimental rat group at weekly intervals. A-F, rat groups A-F corresponding to in Table 2 . * Increasing ratio=(average of body weight before therapy)/(average of body weight at 4th week). Note: In groups A,B,C, and D individual rats were given xeno geneic I-RNA in doses of 30 mg/kg (50-fold of conventional dose), 15 mg/kg (25-fold), 7.5 mg/kg (12.5-fold) and 3.75 mg/kg (6 .25-fold), respectively. Rats in group E received 1 ml of normal saline solution intraperitoneally once a day for 30 days.
No treatment was given to rats in group F. Hematological study.
There was no significant difference among the groups Table 3 ).
Biochemical study. Statistical analysis disclosed that the values of GOT , GPT and LDH were higher in groups A and B than in the control groups E and F (p< 0.05). There was no significant difference in groups C and D or in the other factors measured (Table 4) .
Pathological study. The main pathological finding in the liver was vacuolar degeneration of hepatic cells, and it was prominent in groups A and B (Table 5) . Table 6 shows the distribution of main findings in the kidney, lymph node, spleen and lung.
In the kidney, an increase of mesangial matrix and polynucleation of the glomerulus were found more frequently in groups A and B than in the other groups. In lymph nodes, follicular hyperplasia was more frequent in groups A and B.
There was no significant difference in extramedullary hematopoiesis, megakaryo cytosis and hemosiderosis of the spleen or interstitial pneumonitis among the groups. There were no significant pathological findings in the heart, thymus, intestine, adrenal gland, bone, bone marrow, testicle or epididymis. Hematological and biochemical study. Results of hematological and biochemical study are shown in Table 7 . There was no significant difference among them before and after the immunotherapy (Table 7) .
Pathological findings. The pathological findings in three patients treated with immunotherapy and five controls with gastric cancer are depicted in Table 8 . In the liver, two of three patients treated had a mild degree of vacuolar degenera tion of hepatic cells and hemosiderosis and one had a slight infiltration of inflammatory cells into Glisson's sheath . In the kidney, no significant findings were found. In the lung, two of three patients treated had slight evidence of interestitial pneumonitis, and one had slight thickening of the pleura. In the spleen, •õ Degeneration of fatty cells in the pericardium.
•ö Slight proliferation of collagen fibers around vessels.
• It has been established that xenogeneic I-RNA mediates cytotoxic immune reactions against human cancer cells in vitro . However, there is no report on the toxicity of xenogeneic I-RNA. Pilch et al. (1976) reported favorable results with use of sheep I-RNA which was administered intradermally to 35 patients and improvement was noticed in 4 patients. The therapy was free of significant local or systemic toxicity and was tolerated very well. However, there are few reports on clinical application of passive im munotherapy with transfusion of allogeneic lymphocytes preincubated with xenogeneic I-RNA.
In the present experimental study, there was no death among the treated or control group during the experimental period. In the groups A and B, which received 50-fold (30 mg/kg) of conventional dose of I-RNA and 25-fold (15 mg/kg) I-RNA, respectively, there were a decrease in oral intake, poor increase in body weight, elevation of GOT, GPT and LDH and more frequent findings of vacuolar degeneration of the hepatic cells, proliferation of mesangial matrix, polynucleation of the glomerulus, and follicular hyperplasia of the lymph nodes. On the other hand, group C or D which received 12.5-fold (7.5 mg/kg) I-RNA and 6.25-fold (3.75 mg/kg) I-RNA, respectively, showed no significant difference from control groups. Therefore, it can be concluded that 7.5 mg/kg of I-RNA would be the maximum safe dose. However, it is difficult to conclude that these findings are due to xenogeneic I-RNA treated lymphocytes, because so many factors affect the end stage patient with cancer.
Although much work is to be done for the safe clinical application of xenogeneic I-RNA, it is concluded that passive immunotherapy with allogeneic lymphocytes sensitized with xenogeneic I-RNA is a safe modality in immunotherapy.
